文献速递妇科生殖医学

利用组学数据开展卵巢衰老的药物发现与开发

Harnessing omics data for drug discovery and development in ovarian aging.
PubMed 文献 · Hum Reprod Update · 2025-01-01

本综述综合基因组、转录组、蛋白质组、代谢组和微生物组等多组学数据,从组织水平和单细胞层面梳理卵巢衰老的分子机制,并探讨如何利用这些数据识别新药靶点、指导延缓或逆转卵巢衰老的治疗策略,检索截至2024年9月的英文文献。

要点

  • 多组学研究揭示卵巢衰老涉及DNA损伤修复缺陷、炎症与免疫反应、线粒体功能障碍和细胞死亡等机制。
  • 整合多组学数据可识别BRCA2、TERT、Tet、FTO、sirtuins、CD38+、BIN2、PDGF-BB、FOXP1等潜在药靶。
  • 单细胞技术与空间转录组学结合AI模型,有望更准确地预测候选药物靶点。

核心结论

  • 多组学数据整合有助于识别卵巢衰老的关键调控因子和潜在药物靶点,单细胞多组学数据与AI模型结合有望更准确预测候选药物靶点,为卵巢衰老的个性化医疗和精准治疗提供新途径。

研究设计与样本

  • 本综述在PubMed数据库检索截至2024年9月发表的英文文献,纳入与卵巢衰老相关的多组学数据,涵盖基因组、转录组、表观基因组、蛋白质组、代谢组、脂质组、微生物组及单细胞层面,并从组织水平和单细胞角度进行综合。

主要发现

  • 多组学研究揭示卵巢衰老的关键机制包括DNA损伤与修复缺陷、炎症与免疫反应、线粒体功能障碍和细胞死亡。
  • 已识别的潜在药物靶点包括遗传靶点BRCA2和TERT、表观遗传靶点Tet和FTO、代谢靶点sirtuins和CD38+、蛋白靶点BIN2和PDGF-BB以及转录因子FOXP1。
  • 单细胞技术和空间转录组学等前沿组学技术为治疗决策提供信息,并成为减缓或逆转卵巢衰老药物发现的有力工具。

关键数值与推荐

  • 综述汇总的潜在药物靶点包括:遗传靶点BRCA2、TERT;表观遗传靶点Tet、FTO;代谢靶点sirtuins、CD38+;蛋白靶点BIN2、PDGF-BB;转录因子FOXP1。

临床怎么用

  • 作者认为,单细胞多组学数据与AI模型整合有望更准确地预测候选药物靶点,为卵巢衰老的个性化医疗和精准治疗提供新途径。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ovarian aging occurs earlier than the aging of many other organs and has a lasting impact on women's overall health and well-being. However, effective interventions to slow ovarian aging remain limited, primarily due to an incomplete understanding of the underlying molecular mechanisms and drug targets. Recent advances in omics data resources, combined with innovative computational tools, are offering deeper insight into the molecular complexities of ovarian aging, paving the way for new opportunities in drug discovery and development. OBJECTIVE AND RATIONALE: This review aims to synthesize the expanding multi-omics data, spanning genome, transcriptome, proteome, metabolome, and microbiome, related to ovarian aging, from both tissue-level and single-cell perspectives. We will specially explore how the analysis of these emerging omics datasets can be leveraged to identify novel drug targets and guide therapeutic strategies for slowing and reversing ovarian aging. SEARCH METHODS: We conducted a comprehensive literature search in the PubMed database using a range of relevant keywords: ovarian aging, age at natural menopause, premature ovarian insufficiency (POI), diminished ovarian reserve (DOR), genomics, transcriptomics, epigenomics, DNA methylation, RNA modification, histone modification, proteomics, metabolomics, lipidomics, microbiome, single-cell, genome-wide association studies (GWAS), whole-exome sequencing, phenome-wide association studies (PheWAS), Mendelian randomization (MR), epigenetic target, drug target, machine learning, artificial intelligence (AI), deep learning, and multi-omics. The search was restricted to English-language articles published up to September 2024. OUTCOMES: Multi-omics studies have uncovered key mechanisms driving ovarian aging, including DNA damage and repair deficiencies, inflammatory and immune responses, mitochondrial dysfunction, and cell death. By integrating multi-omics data, researchers can identify critical regulatory factors and mechanisms across various biological levels, leading to the discovery of potential drug targets. Notable examples include genetic targets such as BRCA2 and TERT, epigenetic targets like Tet and FTO, metabolic targets such as sirtuins and CD38+, protein targets like BIN2 and PDGF-BB, and transcription factors such as FOXP1. WIDER IMPLICATIONS: The advent of cutting-edge omics technologies, especially single-cell technologies and spatial transcriptomics, has provided valuable insights for guiding treatment decisions and has become a powerful tool in drug discovery aimed at mitigating or reversing ovarian aging. As technology advances, the integration of single-cell multi-omics data with AI models holds the potential to more accurately predict candidate drug targets. This convergence offers promising new avenues for personalized medicine and precision therapies, paving the way for tailored interventions in ovarian aging. REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Zhang F, Zhu M, Chen Y, et al. Harnessing omics data for drug discovery and development in ovarian aging. Hum Reprod Update. 2025. PMID: 39977580. doi:10.1093/humupd/dmaf002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。